Basics Ardelyx, Inc. Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. IPO Date: June 19, 2014 Sector: Healthcare Industry: Biotech Market Cap: $1.45B Activated in VL: True Average Daily Range Avg Daily Range: $0.23 | 3.21% Avg Daily Range (30 D): $0.15 | 2.65% Avg Daily Range (90 D): $0.12 | 2.02% Institutional Daily Volume Avg Daily Volume: 2.4M Avg Daily Volume (30 D): 3.21M Avg Daily Volume (90 D): 3.18M Trade Size Avg Trade Size (Sh.): 261 Avg Trade Size (Sh.) (30 D): 157 Avg Trade Size (Sh.) (90 D): 162 Institutional Trades Total Inst.Trades: 1,537 Avg Inst. Trade: $2.19M Avg Inst. Trade (30 D): $1.71M Avg Inst. Trade (90 D): $1.92M Avg Inst. Trade Volume: .43M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.88M Avg Closing Trade (30 D): $1.91M Avg Closing Trade (90 D): $2.26M Avg Closing Volume: 541.01K     News Jun 2, 2025 @ 5:50 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: N/A May 21, 2025 @ 12:00 PM Ardelyx to Participate at the Jefferies Global Hea... Source: N/A Apr 24, 2025 @ 12:01 PM Ardelyx Announces Three Abstracts Accepted for Pos... Source: N/A Feb 19, 2025 @ 1:01 PM Ardelyx to Present at the TD Cowen 45th Annual Hea... Source: Ardelyx, Inc. Jan 6, 2025 @ 1:00 PM Ardelyx to Present at the 43rd Annual J.P. Morgan ... Source: N/A Financials   TTM Q3 2025 Q2 2025 Basic EPS $-.23 $ $-.08 Diluted EPS $-.23 $ $-.08 Revenue $ 398.23M $ 110.33M $ 97.66M Gross Profit $ 351.28M $ 106.35M $ 85.26M Net Income / Loss $ -56.55M $ -.97M $ -19.08M Operating Income / Loss $ -37.95M $ 4.67M $ -14.4M Cost of Revenue $ 46.95M $ 3.98M $ 12.4M Net Cash Flow $ -4.71M $ -47.33M $ 59.24M PE Ratio